SHEPHERD is different from other pharmaceutical companies because we ask: “What approaches can save the lives of rare cancer patients?,” rather than: “What disease can I address with my approach?”

SHEPHERD is committed to developing a “new normal” – an ultra-fast, ultra-efficient process for rare cancers.


Most companies begin with a scientific discovery that is translated into a therapeutic approach.  They start with a solution, then apply that solution to a disease that may benefit from it. 

SHEPHERD started with a mission and determination to conquer a problem.  Millions of people are diagnosed with rare cancers for which there are no treatment options.  Yet, we believe that the technology, understanding, expertise, and resources that could treat those diseases and save those lives do exist.  

Our process is designed to seek out the best therapeutics and delivery mechanisms for rare cancer patients. This process allows us to think critically about the underlying cause of the disease and to identify and test the most promising strategies relevant to rare cancer. This allows SHEPHERD to truly be platform agnostic.


Our goal is to discover and develop cures for patients diagnosed with rare cancers. We focus on areas of high, unmet need: rare cancer indications with high mortality rates and few therapeutic options beyond resection and radiation.  We strive to match each biological target with the optimal technology platform in order to develop a life-saving therapeutic specifically for that indication.

SHEPHERD’s approach prioritizes the convergence of life science, social science, and computation. SHEPHERD uses a proprietary software, that combines deep learning artificial intelligence and proprietary algorithms with traditional quantitative and qualitative statistical analysis.  We start by mapping the mutational landscape (every known target and pathway) of every rare cancer, then add in significant qualitative variables related to patient profile, environmental data, and demographics to inform the best treatment modality.  Our ability to identify target overlap, combined with our deep knowledge of each cancer, allows us to engineer an optimal therapeutic combination and delivery technology for multiple rare cancers.

Projects in our pipeline are currently in the preclinical phase of development. External collaborations and opportunities are also being pursued with the National Cancer Institute and the Massachusetts Institute of Technology.


Our platform integrates expertise in rare diseases, orphan drug development, gene therapy, neuro-immunology, immuno-oncology, pharmacology, applied math and computational science. 


SHEPHERD actively pursues strategic partnerships with academic institutions, government agencies, patient foundations, and other biopharmaceutical companies who share our commitment to saving the lives of rare cancer patients.

If you have a technology or therapeutic that may benefit rare cancer patients, please contact us.